KIAA0317 Inhibitors
Chemical inhibitors of KIAA0317 can achieve functional inhibition through various mechanisms by targeting pathways that are crucial for the protein's activity. Alsterpaullone, Roscovitine, and Olomoucine are known to inhibit cyclin-dependent kinases (CDKs), which play a pivotal role in cell cycle regulation. By impeding these kinases, these inhibitors can prevent necessary phosphorylation events, which are required for KIAA0317's activity within its specific cellular pathways. SP600125, a c-Jun N-terminal kinase (JNK) inhibitor, can disrupt the stress response signaling pathways where KIAA0317 is active. Similarly, SB203580, by inhibiting p38 MAP kinase, can block signaling pathways that rely on this kinase's activity for the functional operation of KIAA0317 in response to cellular stress or cytokine signaling.
Further, LY294002 and Wortmannin, as phosphatidylinositol 3-kinase (PI3K) inhibitors, can disrupt the PI3K/AKT pathway, which is essential for various cellular processes in which KIAA0317 is involved, including cell survival, proliferation, and metabolism. Rapamycin, by inhibiting the mammalian target of rapamycin (mTOR), can affect KIAA0317's role in pathways related to cell growth and proliferation. PD98059 and U0126 are inhibitors of the MAP kinase/ERK pathway, which can prevent the activation of ERK1/2 kinases that may be necessary for KIAA0317's signal transduction functions. Leflunomide inhibits dihydroorotate dehydrogenase, leading to a reduction in pyrimidine synthesis, which can indirectly affect KIAA0317's activity in cell proliferation and transcription. Lastly, Bortezomib, a proteasome inhibitor, can prevent the degradation of proteins within the ubiquitin-proteasome pathway, an essential process for the regulation of the cell cycle and apoptosis, where KIAA0317's functionality is likely to be crucial.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone is a cyclin-dependent kinase inhibitor that can inhibit CDKs which are important for cell cycle regulation. Inhibition of these kinases can lead to the functional suppression of KIAA0317 by preventing necessary phosphorylation events that are required for KIAA0317's activity within its specific cellular pathways. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine selectively inhibits CDKs, which could lead to a reduction in phosphorylation of proteins involved in the same pathway as KIAA0317, thereby functionally inhibiting KIAA0317 by indirectly preventing its proper regulation within the cell cycle or other processes where CDKs are required for KIAA0317 function. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is another CDK inhibitor that can indirectly inhibit KIAA0317 by blocking the phosphorylation of proteins that are in the same pathway as KIAA0317, potentially leading to a functional inhibition of KIAA0317 through impaired signal transduction necessary for its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in regulatory pathways that could affect proteins such as KIAA0317. By inhibiting JNK, SP600125 could lead to a functional inhibition of KIAA0317 through impaired stress response signaling pathways where KIAA0317's activity is necessary. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor that could functionally inhibit KIAA0317 by blocking the signaling pathways that rely on p38 MAP kinase activity, which may be necessary for the proper function of KIAA0317 in response to cellular stress or cytokine signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a phosphatidylinositol 3-kinase (PI3K) inhibitor, which could functionally inhibit KIAA0317 by disrupting the PI3K/AKT pathway, a pathway that could be essential for KIAA0317's function in processes such as cell survival, proliferation, and metabolism. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, which could lead to functional inhibition of KIAA0317 by impeding the PI3K/AKT pathway, potentially affecting the regulation and activity of KIAA0317 within this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR), which is central to a pathway that could be necessary for KIAA0317 function related to cell growth and proliferation. Inhibition of mTOR could therefore functionally inhibit KIAA0317's role within this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of the MAP kinase/ERK pathway, which could functionally inhibit KIAA0317 by preventing the activation of ERK1/2, kinases that may be necessary for KIAA0317 activity in signal transduction related to growth and differentiation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MAP kinase/ERK pathway inhibitor that could lead to functional inhibition of KIAA0317 by preventing the phosphorylation of ERK1/2, potentially affecting KIAA0317's function within this signaling pathway. | ||||||